Walgreens Boots Alliance Inc (NASDAQ:WBA) – Stock analysts at Svb Leerink dropped their Q2 2019 earnings per share estimates for shares of Walgreens Boots Alliance in a research note issued on Friday, March 29th, Zacks Investment Research reports. Svb Leerink analyst D. Larsen now forecasts that the pharmacy operator will post earnings of $1.68 per share for the quarter, down from their previous estimate of $1.70. Svb Leerink also issued estimates for Walgreens Boots Alliance’s Q3 2019 earnings at $1.64 EPS, Q4 2019 earnings at $1.62 EPS and FY2019 earnings at $6.40 EPS.
Walgreens Boots Alliance (NASDAQ:WBA) last posted its quarterly earnings results on Tuesday, April 2nd. The pharmacy operator reported $1.64 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.70 by ($0.06). Walgreens Boots Alliance had a net margin of 3.77% and a return on equity of 22.00%. The business had revenue of $34.53 billion during the quarter, compared to analysts’ expectations of $34.57 billion. During the same quarter in the previous year, the business posted $1.73 EPS. The company’s quarterly revenue was up 4.6% on a year-over-year basis.
NASDAQ:WBA traded up $0.25 during trading hours on Monday, hitting $53.47. The stock had a trading volume of 5,992,240 shares, compared to its average volume of 6,797,218. The company has a quick ratio of 0.38, a current ratio of 0.78 and a debt-to-equity ratio of 0.50. Walgreens Boots Alliance has a 1-year low of $53.17 and a 1-year high of $86.31. The company has a market capitalization of $49.95 billion, a price-to-earnings ratio of 8.88, a price-to-earnings-growth ratio of 1.11 and a beta of 0.86.
The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 12th. Shareholders of record on Monday, May 20th will be paid a $0.44 dividend. This represents a $1.76 dividend on an annualized basis and a yield of 3.29%. The ex-dividend date of this dividend is Friday, May 17th. Walgreens Boots Alliance’s payout ratio is 29.24%.
In related news, COO Ornella Barra bought 18,000 shares of the business’s stock in a transaction on Wednesday, April 3rd. The shares were bought at an average cost of $54.56 per share, for a total transaction of $982,080.00. Following the completion of the purchase, the chief operating officer now owns 26,425 shares of the company’s stock, valued at approximately $1,441,748. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 15.73% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of WBA. CSat Investment Advisory L.P. grew its holdings in Walgreens Boots Alliance by 12.1% during the fourth quarter. CSat Investment Advisory L.P. now owns 1,920 shares of the pharmacy operator’s stock worth $131,000 after acquiring an additional 208 shares during the period. Pathlight Investors LLC acquired a new position in Walgreens Boots Alliance during the fourth quarter worth about $524,000. James Investment Research Inc. acquired a new position in Walgreens Boots Alliance during the fourth quarter worth about $963,000. Tiemann Investment Advisors LLC grew its holdings in Walgreens Boots Alliance by 2.7% during the fourth quarter. Tiemann Investment Advisors LLC now owns 22,190 shares of the pharmacy operator’s stock worth $1,516,000 after acquiring an additional 586 shares during the period. Finally, Newman Dignan & Sheerar Inc. grew its holdings in Walgreens Boots Alliance by 22.9% during the first quarter. Newman Dignan & Sheerar Inc. now owns 4,616 shares of the pharmacy operator’s stock worth $292,000 after acquiring an additional 861 shares during the period. Institutional investors and hedge funds own 65.05% of the company’s stock.
About Walgreens Boots Alliance
Walgreens Boots Alliance, Inc operates as a pharmacy-led health and wellbeing company. It operates through three segments: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. The Retail Pharmacy USA segment sells prescription drugs and an assortment of retail products, including health, beauty, personal care, consumable, and general merchandise products through its retail drugstores and convenient care clinics.
Read More: Why is total return important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Walgreens Boots Alliance Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Walgreens Boots Alliance and related companies with MarketBeat.com's FREE daily email newsletter.